Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $5.92 Consensus Price Target from Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $5.92.

A number of analysts have issued reports on XERS shares. Leerink Partners lifted their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Piper Sandler restated a "neutral" rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group restated a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, Craig Hallum upped their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 7th.

Institutional Trading of Xeris Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp raised its position in Xeris Biopharma by 446.0% in the 4th quarter. Mackenzie Financial Corp now owns 129,952 shares of the company's stock worth $441,000 after purchasing an additional 106,153 shares during the period. Squarepoint Ops LLC raised its position in Xeris Biopharma by 118.2% in the 4th quarter. Squarepoint Ops LLC now owns 40,769 shares of the company's stock worth $138,000 after purchasing an additional 22,084 shares during the period. Two Sigma Advisers LP purchased a new stake in Xeris Biopharma in the 4th quarter worth about $47,000. Stonepine Capital Management LLC purchased a new stake in Xeris Biopharma in the 4th quarter worth about $618,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Xeris Biopharma in the 4th quarter worth about $79,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Xeris Biopharma Stock Up 5.7 %

NASDAQ XERS traded up $0.26 on Monday, reaching $4.82. The company had a trading volume of 6,592,961 shares, compared to its average volume of 2,220,154. The stock has a market capitalization of $741.99 million, a PE ratio of -10.71 and a beta of 2.32. The firm's 50 day moving average price is $3.68 and its 200 day moving average price is $3.31. Xeris Biopharma has a 12 month low of $1.69 and a 12 month high of $4.90.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.